Edition:
India

MiMedx Group Inc (MDXG.OQ)

MDXG.OQ on NASDAQ Stock Exchange Capital Market

7.40USD
1:30am IST
Change (% chg)

$-0.10 (-1.33%)
Prev Close
$7.50
Open
$7.46
Day's High
$7.54
Day's Low
$7.16
Volume
500,682
Avg. Vol
866,152
52-wk High
$18.24
52-wk Low
$6.05

Select another date:

Wed, Mar 28 2018

BRIEF-MiMedx Enrolls First Patient In Its Phase 2B Clinical Trial Of Amniofix® Injectable For Treatment Of Osteoarthritis Of The Knee

* MIMEDX ENROLLS FIRST PATIENT IN ITS PHASE 2B CLINICAL TRIAL OF RMAT DESIGNATED AMNIOFIX® INJECTABLE FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE Source text for Eikon: Further company coverage:

BRIEF-Mimedx Reports Positive Results From Phase 2B Clinical Trial Of Amniofix Injectable

* MIMEDX REPORTS POSITIVE PAIN AND FOOT FUNCTION RESULTS FROM PHASE 2B CLINICAL TRIAL OF AMNIOFIX® INJECTABLE IN THE TREATMENT OF PLANTAR FASCIITIS

BRIEF-MiMedx Says "Confident" in Q1 Rev Guidance, Discloses DoJ Investigation

* MIMEDX ANNOUNCES EXPECTATION TO EXCEED THE $92 MILLION TOP END OF FIRST QUARTER REVENUE GUIDANCE

BRIEF-Mimedx's Amniofix Injectable Granted RMAT Designation By FDA

* AMNIOFIX INJECTABLE GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION BY THE FDA FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE

BRIEF-Mimedx Group Files For Non-Timely 10-K - SEC Filing

* MIMEDX - NOT ABLE TO PROVIDE QUANTITATIVE DESCRIPTION OF CHANGES IN RESULTS BETWEEN 2017, PRIOR PERIODS UNTIL AUDIT COMMITTEE COMPLETES INVESTIGATION Source text (http://bit.ly/2t9DPzh) Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Mimedx Comments On Magistrate Recommendation In Co's Lawsuit Against Short Sellers

* MIMEDX COMMENTS ON MAGISTRATE RECOMMENDATION IN THE COMPANY'S LAWSUIT AGAINST SHORT SELLERS

BRIEF-Mimedx Announces First Patients Have Been Enrolled In The Phase 3 Clinical Trial Of Amniofix

* MIMEDX ANNOUNCES FIRST PATIENTS HAVE BEEN ENROLLED IN THE PHASE 3 CLINICAL TRIAL OF AMNIOFIX® INJECTABLE IN PATIENTS WITH RECALCITRANT PLANTAR FASCIITIS PAIN

BRIEF-Mimedx Settles Patent Infringement Lawsuit

* MIMEDX - SUCCESSFULLY SETTLED CO'S PATENT INFRINGEMENT LAWSUIT AGAINST MUSCULOSKELETAL TRANSPLANT FOUNDATION, MEDLINE INDUSTRIES, LIVENTA BIOSCIENCE

BRIEF-MiMedx Agrees To Lawsuit Settlement With Former Employee

* MIMEDX GROUP INC - COMPANY HAS AGREED TO A CONFIDENTIAL LAWSUIT SETTLEMENT FROM ONE FORMER EMPLOYEE

BRIEF-MiMedx Forecasts 2018 Revenue To Be In Range Of $383 Mln To $387 Mln

* MIMEDX FORECASTS 2018 REVENUE TO BE IN THE RANGE OF $383 MILLION TO $387 MILLION

Select another date: